Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here.
You are subscribed to Ophthalmology Times Europe.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
In this issue
New technology
Endophthalmitis
DME therapy
 
 
Survey

Do you assess dry eye preoperatively?

Yes
20%
No
80%

You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Felicity Thomas, editor.


February 26, 2014
Technology update
New lenses show promise for sustained glaucoma treatment
Researchers at University of California, Los Angeles, USA, have developed a new delivery system for treating patients with glaucoma. They have combined nanodiamonds — a by-product of conventional mining and refining processes — with timolol maleate into contact lenses that deliver sustained doses. More...
Clinical research
Microbiological spectrum of post-traumatic endophthalmitis unchanged
The microbiological spectrum in patients with post-traumatic endophthalmitis has remained unchanged over the past 14 years, with Bacillus spp. still the most commonly found infecting organism, and vancomycin remaining the drug of choice for empiric coverage of gram-positive bacteria. More...
DME therapy update
Ranibizumab may improve retinal function and structure in DME
Treatment of diabetic macular oedema (DME) with ranibizumab may improve retinal function and structure, according to researchers from the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital and University College, London Institute of Ophthalmology. More...
Ranibizumab leading the anti-VEGF evolution
Considerations and new perspectives in anti-VEGF therapy. Read more:
Choosing and using the AcrySof IQ ReSTOR IOL family
Customize
d options for individual patients. Read more:
The Safety of anti-VEGF Therapy
Under the microscope, in trials and in clinical practice. Read more: